European Hospital Financing Reform - Developments and Business Implications

3.1 Belgium and the Netherlands
Belgium
Healthcare Financing
The compulsory health insurance system
Controlling mutuality costs

3.2 France
Healthcare System
Health Funding
The delivery system
Cost containment
Stability Programme, 2004- 2006

3.3 Germany
Health Expenditure
The Health System
Cost containment measures

3.4 Italy
Healthcare Financing
Moves to stifle growth in private insurance
Cost containment measures
National Health Plan 2003-2005

3.5 United Kingdom
Healthcare System
Healthcare Financing
Growing disillusionment with NHS service delivery

3.6 Scandinavia
Denmark
Healthcare System
Sweden
Healthcare System

3.7 Spain

4. Hospital Financing and the shift to DRG-based reimbursement for services
HISTORY AND BACKGROUND OF DRGs

4.1 Belgium and the Netherlands
Legislative reform and business implications
Hospital Financing
Legislative reform
Business Implications

4.2 France
Hospital Financing
Legislative reform
Hospital Restructuring
Hôpital 2007 - Targeting Hospital Modernization
Increasing attractiveness of the DRG model of financing

4.3 Germany
Hospital Financing
Legislative reform

4.4 Italy
Hospital Financing
Legislative reform
Business Implications

4.5 United Kingdom
Hospital Financing Mechanisms
Legislative reform
HRGs targeting waiting lists
HRG Development

4.6 Sweden
Legislative reforms

5. The impact of DRGs on reimbursement in selected disease/treatment areas

5.1 Implantable cardioverter defibrillators
5.1.1. ICD therapy in the treatment of arrhythmia and complications
5.1.2. The role of ICDs in prophylaxis of SCD
5.1.3. Cost-effectiveness assessments
5.1.4. DRG and reimbursement impact on ICD implantation rates - US Recommendations
5.1.5. European ICD Implant Rates

5.2 Drug-Eluting Stents
5.2.1 Creation of new DRGs to cover stent reimbursement and encourage utilization

6. Health Technology Assessment (HTA) - its expanding role in medical device diffusion.

6.1 HTA activity in Europe
6.1.1 Benelux
6.1.2 France
6.1.3 Germany
HTAs and the maintenance and development of public benefit catalogues in Germany
HTA reports used to detect over-, under- and misuse of medical technologies
6.1.4 Italy
6.1.5 Spain
6.1.6 United Kingdom
NICE guidance has role in UK local health policy
6.1.7 Scandinavia

6.2 Relevant case studies - The NICE approach and impact
Selection of prostheses for primary total hip replacement - Guidance number 2

7. The anticipated impact of DRG implementation in Germany

7.1 DRGs in the USA and Australia - Any lessons to be learnt for device manufacturers?
The Australian Medical Devices Market
The United States Health Care System
DRG and cost-containment in the secondary care sector
Technology diffusion in the USA

8. Corporate Strategies - Positioning in an era of increasing reform